June 18, 2014 / 4:13 PM / in 3 years

BUZZ-U.S. Stocks on the Move-ZS Pharma, Insmed, MeetMe, BlackBerry

(For faster updates on individual market-movers, use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s)

U.S. stocks were little changed Wednesday, on the heels of a three-day winning streak for the S&P 500 index. The Dow Jones industrial average was down 0.24 percent at 16,768.94 and the S&P 500 was down 0.07 percent at 1,940.64.

** ZS PHARMA INC, $27.89, +54.94 pct

The biopharmaceutical company’s shares up 51.7 percent at $27.42 in their debut, valuing the company at about $514 million. ZS Pharma raised $90 million after its IPO of 5 million shares was priced at $18 per share, higher than the expected range of $15-$17

** INSMED INC, $17.39, +39.51 pct

U.S. FDA granted breakthrough therapy designation to the drug developer’s experimental lung infection drug. The designation can accelerate review for drugs that show substantial benefit over available therapies.

** ADOBE SYSTEMS INC, $72.2101, +6.91 pct

The maker of Photoshop and Acrobat software reported better-than-expected quarterly profit and revenue, helped by higher subscription sales of its Creative Cloud and Marketing Cloud suites.

Brokerage JMP Securities raised its price target on Adobe’s stock to $82 from $78. Susquehanna Financial Group raised its target price to $87 from $83. RBC Capital Markets raised its target price to $85 from $75.

** ENDOCYTE INC, $6.5, -15.80 pct

The drug developer said Merck & Co Inc would no longer pursue the development of Endocyte’s cancer drug, vintafolide. Vintafolide is being developed to deliver chemotherapy drugs directly to cancer cells and is being tested in patients with lung and breast cancer.

** ENTEROMEDICS INC, $1.73, +13.82 pct

The medical device maker said a U.S. FDA panel voted 6-2 in favor of its obesity device. EnteroMedics device helps treat obesity by controlling hunger and blocking the primary nerve that regulates the digestive system.

** LA-Z-BOY INC, $22.63, -8.90 pct

The company, known for its La-Z-Boy recliners, reported lower-than-expected revenue for the fourth quarter. Same-store sales declined 0.9 percent.

** AIR PRODUCTS & CHEMICALS INC, $130.06, +6.96 pct

The industrial gas producer under pressure from Bill Ackman to overhaul its management, said it has appointed Seifi Ghasemi chief executive. Ghasemi, currently CEO of specialty chemicals maker Rockwood Holdings Inc, replaces John McGlade.

** MEETME INC, $2.248, +16.48 pct

Wunderlich Securities initiates coverage on the social media technology company with “buy” and price target of $4.50. Enhancements to MeetMe’s main mobile app to help increase active users, brokerage said. All four analysts covering the stock have “buy” or “strong buy” on it

** SIGNAL GENETICS INC, $8.81, -11.90 pct

The diagnostic company’s shares fell 11.8 percent to $8.54 in their debut, valuing the company at about $34 million. Signal Genetics raised $8.5 million after its IPO of 850,000 shares was priced at $10 each, at the low end of its expected range of $10-$12.

** FEDEX CORP, $147.08, +4.83 pct

The world No. 2 package delivery company reported a better-than-expected quarterly profit as strong shipments of items ordered online boosted its ground business. FedEx also said earnings for 2015 should benefit from ongoing cost cutting and restructuring.

** CONAGRA FOODS INC, $30.37, -7.55 pct

** KELLOGG CO, $66.07, -0.94 pct

The maker of Hunt’s tomato ketchup and Slim Jim beef jerky said its adjusted fourth-quarter profit would be below its forecast due to lower sales in its consumer foods business and weak profits in private brands.

Shares of Kellogg were slightly down.

** WALGREEN CO, $74.9, +2.46 pct

Barclays Capital raised its rating on the drugstore operator’s stock to “overweight” from “equal weight”, saying the company was considering changes that could materially boost earnings and the stock price. Potential changes include reducing expenses and optimizing the capital structure, and inverting the existing corporate structure to achieve tax savings, analyst Meredith Adler wrote in a note, raising the price target to $92 from $56.

** GW PHARMACEUTICALS PLC, $85.63, -4.66 pct

The drugmaker’s American depositary shares fell after the UK-based company said it planned to sell 1.7 million of its ADRs in a public offering. The price of the offering has not been decided.

** BLACKBERRY LTD, $8.3265, +3.43 pct

The Canadian smartphone maker is set to unveil a licensing deal with Amazon.com Inc, sources said. The Deal would allow the company to offer about 240,000 Android apps from Amazon’s app store on new BlackBerry’s devices.

** LIVEDEAL INC, $4.2599, +12.70 pct

The number of restaurants registered with the internet marketing company’s real-time “deal engine” on a daily basis rose 400 pct. A 35-city campaign helped drive traffic into more than 8,000 associated restaurants.

** BALLARD POWER SYSTEMS INC, $3.789, +6.43 pct

Jennings Capital initiated coverage on the Canadian fuel cell maker’s stock with “buy” and price target of $40. Analysts said Ballard’s recent patent acquisitions from United Technologies Corp would help it focus better on auto sector and strengthen its position as preferred engineering partner.

** SUNPOWER CORP, $39.2272, -2.48 pct

JP Morgan analysts downgrade the solar panel maker’s stock to “neutral” from “overweight”, citing its 35 percent run up this year. They said they are confident on Sunpower’s business due to low cost of capital and strong momentum in distributed rooftop solar business.

** ACTUANT CORP, $34.71, -4.38 pct

The industrial products maker cuts full-year profit forecast, partly due to weak mining industry. The company forecast full-year earnings of $1.92-$1.97 per share, below previous estimate of $2.00-$2.10

** FORESIGHT ENERGY LP, $19.15, -4.25 pct

Foresight Energy’s units fell more than 2 percent in their market debut, after the coal producer’s IPO was priced at the midpoint of its expected price range. The company raised $350 million after the offering of $17.5 million common units, representing limited partner interests, were priced at $20 each.

** ZALICUS INC, $1.34, +7.20 pct

The drug developer licensed experimental painkiller to privately held AnaBios Corp. Zalicus may receive up to $17.2 million in milestone payments and up to 12 percent of net sales.

** RECEPTOS INC, $41.5, +7.85 pct

The drug developer said it would sell its common stock, procceds of which will go to fund trials for multiple sclerosis drug and other treatments. Receptos said in a filing on June 11 it plans to raise up to $150 million

** NGL ENERGY PARTNERS LP, $42.95, -5.96 pct

The propane gas supplier priced the offering of 8 million units at $43.85 per unit. NGL intends to use net proceeds to repay debt and for capital expenditures and potential acquisitions.

** TAUBMAN CENTERS INC, $75.18, +2.04 pct

The shopping mall operator said Starwood Capital would buy seven malls from it, in a deal valued at $1.4 billion.

Compiled by Mridhula Raghavan; Edited by Don Sebastian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below